Vimarsana
Biggest News Aggregation in the World

Page 49 - Us Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Us Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Us Communications Today - Breaking & Trending Today

Hikma Launches New 503B Sterile Compounding Business - Vimarsana News

Hikma Launches New 503B Sterile Compounding Business

/PRNewswire/ -- Hikma Pharmaceuticals PLC ("Hikma"), the multinational pharmaceutical company, announces the launch of Hikma 503B – a new outsourced sterile...

MorphoSys AG: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference - Vimarsana News

MorphoSys AG: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40

In Facebook's 'virtual universe' opinion substitutes for fact -- Society's Child -- Sott.net - Vimarsana News

In Facebook's 'virtual universe' opinion substitutes for fact -- Society's Child -- Sott.net

Facebook likes to present its fact-checkers as impartial arbiters of squeaky-clean truth. The reality, however, shows they are no more bound by the constraints of certainty and infallibility than the users they monitor. Mark Zuckerberg, the...

Source: sott.net
Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners - Vimarsana News

Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners

/PRNewswire/ -- Galderma announced today the new label for SCULPTRA® (injectable poly-L-lactic acid (PLLA)), the first and only FDA-approved PLLA facial...

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva® - Vimarsana News

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®

/PRNewswire/ -- Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license...